Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Charles Van Praet; Charlotte Slots; Nikhil Vasdev; Sylvie Rottey; Valérie Fonteyne; Iulia Andras; Maarten Albersen; Gert De Meerleer; Axel Bex; Karel Decaestecker

doi:10.5152/tud.2021.21006

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Charles Van Praet, Charlotte Slots, Nikhil Vasdev, Sylvie Rottey, Valérie Fonteyne, Iulia Andras, Maarten Albersen, Gert De Meerleer, Axel Bex, Karel Decaestecker

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Abstract

Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

Original language	English
Pages (from-to)	S79-S84
Number of pages	6
Journal	Turkish Journal of Urology
DOIs	https://doi.org/10.5152/tud.2021.21006
Publication status	Published - 1 Feb 2021

Access to Document

10.5152/tud.2021.21006Licence: Unspecified

Accepted_Version
© 2021 by Turkish Association of Urology. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.5152/tud.2021.21006
Accepted author manuscript, 260 KBLicence: Unspecified

Cite this

@article{a704a32f51a541608847a2c9014e1d40,

title = "Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma",

abstract = "Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.",

author = "{Van Praet}, Charles and Charlotte Slots and Nikhil Vasdev and Sylvie Rottey and Val{\'e}rie Fonteyne and Iulia Andras and Maarten Albersen and {De Meerleer}, Gert and Axel Bex and Karel Decaestecker",

note = "{\textcopyright} 2021 by Turkish Association of Urology. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.5152/tud.2021.21006",

year = "2021",

month = feb,

day = "1",

doi = "10.5152/tud.2021.21006",

language = "English",

pages = " S79--S84 ",

journal = "Turkish Journal of Urology ",

issn = "2149-3057",

publisher = "Aves",

}

TY - JOUR

T1 - Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

AU - Van Praet, Charles

AU - Slots, Charlotte

AU - Vasdev, Nikhil

AU - Rottey, Sylvie

AU - Fonteyne, Valérie

AU - Andras, Iulia

AU - Albersen, Maarten

AU - De Meerleer, Gert

AU - Bex, Axel

AU - Decaestecker, Karel

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

AB - Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.

U2 - 10.5152/tud.2021.21006

DO - 10.5152/tud.2021.21006

M3 - Article

SN - 2149-3057

SP - S79-S84

JO - Turkish Journal of Urology

JF - Turkish Journal of Urology

ER -

Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma

Abstract

Access to Document

Fingerprint

Cite this